StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

This past week, Nektar Therapeutics (Nasdaq: NKTR) offered an uncommon example of victory in court translating into defeat on Wall Street. Nektar’s shares finished Friday flat, dipping 4% from $59.38 to $57.06 despite a jury siding with the San Francisco biotech over Eli Lilly (NYSE: LLY) in a three-year-old legal dispute over the pharma giant’s terminating a collaboration agreement to co-develop Nektar’s lead pipeline candidate rezpegaldesleukin (rezpeg). The post StockWatch: Nektar Shares Flat